A distinguished panel of experts will gather for a comprehensive webinar exploring the evolving landscape of cell and gene therapy (CGT) in rare disease treatment. The event, scheduled for March 5th, 2025, brings together specialists from Bayer Pharmaceuticals and IPG Health to address the challenges and opportunities in this rapidly advancing field.
Current Challenges in Rare Disease Treatment
The rare disease landscape presents unique obstacles for healthcare providers and pharmaceutical companies alike. Many rare conditions currently lack approved treatments, with existing therapies often limited to symptom management or substitution approaches. Clinical trial development faces significant hurdles due to small patient populations and insufficient natural history data, resulting in limited evidence bases for treatment efficacy.
Advancing Cell and Gene Therapy Solutions
Cell and gene therapy has emerged as a promising avenue for addressing rare diseases at their fundamental cellular and genetic levels. Dr. Kristian Johnson, Global Medical Lead for Cell & Gene Therapies at Bayer Pharmaceuticals, brings nearly two decades of clinical and research experience to discuss these innovative approaches. His expertise in ophthalmology and rare diseases positions him to provide valuable insights into the practical applications of CGT.
Expert Perspectives on Implementation
The webinar features an accomplished panel including Imre Varju, SVP Director at YuzuYello, who specializes in patient support programs. His expertise in health communication and behavior models will be crucial in addressing the challenges of therapy implementation and patient adherence.
Lynda Chang and Jane Blyth, Medical Strategy Directors at Complete HealthVizion, will contribute their extensive experience in medical communications and pharmaceutical industry insights. Their combined expertise will help illuminate strategies for effective data dissemination and medical education in the rare disease space.
Future Outlook and Support Strategies
The session will explore various critical aspects of rare disease treatment, including:
- Current treatment landscape analysis
- Development barriers and potential solutions
- CGT implementation strategies
- Healthcare professional and patient support mechanisms
- Future opportunities in the field
Healthcare professionals and industry stakeholders can participate in this virtual event at 3pm GMT (4pm CET, 10am EST) to gain comprehensive insights into the future of rare disease treatment and the expanding role of cell and gene therapies.
